Vertex and CRISPR Therapeutics have announced FDA approval for CASGEVY in treating sickle cell disease. Utilizing cutting edge CRISPR/Cas9 gene editing technology, a patient's own genes are extracted, edited, and then reinserted to eliminate sickle cell in this new therapy.